Safety and Effectiveness of Cytomegalovirus Specific Antigen Induced Interferon-Gamma ELISPOT/ELISA: A Systematic Review
Original article Wonjung Choi1, Joohee Hahn1,2, Worlsook Lee1, Chaemin Shin1 1Division of New Health Technology Assessment, National Evidence-based Healthcare Collaborating Agency, Seoul, 2Review and assessment research department, Health Insurance Review & Assessment Service, Wonju, Korea Corresponding to Chaemin Shin, E-mail: blu0924@neca.re.kr Ann Clin Microbiol 2021;24(2):31-43. https://doi.org/10.5145/ACM.2021.24.2.2Received on 24 February 2021, Revised on 9 April 2021, Accepted on 23 April 2021, Published on 20 June 2021.Copyright © Korean Society of Clinical Microbiology. Abstract Background: This study evaluated the safety and effectiveness of the cytomegalovirus (CMV) Specific Antigen Induced Interferon-Gamma ELISPOT (enzyme-linked immunosorbent spot)/ELISA (enzyme-linked immunosorbent assay) procedure in predicting the risk of CMV infection/disease in immunocompromised patients through a systematic literature review. Methods: The searched electronic databases included MEDLINE, EMBASE and the Cochrane Library. A total of 884 non-duplicate citations were retrieved and a total of 25 studies (15 cohort studies, 10 cross-sectional studies) were included in this review. Study subjects
